MyFinsight
Home
Blog
About
Proceeds from
convertible debt related...
$500K
Net cash provided by
financing activities
$500K
Effect of exchange rate
changes on cash
$1K
(200.00%↑ Y/Y)
Net decrease in cash
and cash...
-$68K
(96.00%↑ Y/Y)
Canceled cashflow
$501K
Accounts payable
$518K
(618.00%↑ Y/Y)
Deferred revenue
$263K
(76.51%↑ Y/Y)
Share-based compensation
expense
$223K
(-78.18%↓ Y/Y)
Accrued and other
current liabilities
$174K
(-49.12%↓ Y/Y)
Prepaid expenses and
other current assets
-$59K
(41.58%↑ Y/Y)
Amortization of operating
lease right-of-use...
$27K
(-43.75%↓ Y/Y)
Inventory
-$15K
(71.70%↑ Y/Y)
Accounts receivable
-$7K
(96.90%↑ Y/Y)
Long-term prepaid
contracts
-$1K
(99.27%↑ Y/Y)
Depreciation
$1K
(-66.67%↓ Y/Y)
Consumer Health Products
$414K
Net cash used in
operating activities
-$569K
(66.51%↑ Y/Y)
Canceled cashflow
$1,288K
Product revenue
$414K
Net loss
-$1,695K
(51.32%↑ Y/Y)
Canceled cashflow
$414K
Insurance premium
financing payable
-$69K
(63.68%↑ Y/Y)
Prepaid research and
development
$65K
(275.68%↑ Y/Y)
Operating lease liability
-$28K
(37.78%↑ Y/Y)
Total operating
expenses
$2,106K
Other segment items
$3K
Research and development
$948K
General and
administrative
$751K
Cost of sales
$391K
Sales and marketing
$16K
Regenerative Biotech
$948K
Consumer Health Products
$391K
Back
Back
Cash Flow
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
Harvard Apparatus Regenerative Technology, Inc. (HRGN)
source: myfinsight.com